Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

Criteria overlap for separating between malignant follicular epithelial cell-derived thyroid
gland neoplasms with high grade features of increased mitoses and tumor necrosis but …

Two-thirds of differentiated thyroid cancer (DTC) patients with distant metastases would be
classified as radioactive iodine-refractory (RAIR-DTC), evolving into a poor outcome. Recent …

Guidelines for the management of differentiated thyroid cancer should continue to reflect
minor regional variations in thyroid cancer treatment based on factors unique to that …

Differentiated thyroid cancer is characteristically associated with an innocuous clinical
course, but a minority of cases may manifest surprisingly aggressive behaviour. Such …

Thyroid cancer constitutes a progressive continuum of disease ranging from indolent well-
differentiated carcinomas to aggressive poorly differentiated carcinomas and universally …

The morbidity of thyroid cancer is increasing gradually year by year, showing an increasing
tendency in nationality, sex, age, tumor size, and tumor staging. The changes of thyroid cell …

Background Although most thyroid cancer patients have an excellent prognosis, 10% of low-
risk cancers and 25% of high-risk cancers recur, with mortality rates in excess of 50% at 3 …

Differentiated thyroid cancers (DTCs) are slow-growing malignant tumours, including
papillary and follicular carcinomas. Overall, prognosis is good, although it tends to worsen …

Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally
an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating …